Granulocyte colony-stimulating factor (G-CSF) is used commonly in an attempt to reduce the duration of neutropenia and hospitalization in patients undergoing chemotherapy and to obtain hematopoietic stem cells (HSC) for transplantation applications. Despite the relative safety of administration of G-CSF in most individuals, including subjects with sickle cell trait, severe and life-threatening complications have been reported when used in individuals with sickle cell disease (SCD), including those who were asymptomatic and undiagnosed prior. The administration of G-CSF has now been reported in a total of 11 individuals with SCD. Seven developed severe adverse events including vaso-occlusive episodes, acute chest syndrome, multi-organ system failure, and death. Precautions including minimizing the peak white blood cell count, dividing or reducing the G-CSF dose, and red blood cell transfusions to reduce HbS levels have been employed with no consistent benefit. These reported data indicate that administration of G-CSF in individuals with SCD should be undertaken only in the absence of alternatives, and after full disclosure of the risks involved. Unless further data demonstrate safety, routine usage of G-CSF in individuals with SCD should be avoided.